<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="hon70104" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Hematol Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Hematol Oncol</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)1099-1069</journal-id><journal-id journal-id-type="publisher-id">HON</journal-id><journal-title-group><journal-title>Hematological Oncology</journal-title></journal-title-group><issn pub-type="ppub">0278-0232</issn><issn pub-type="epub">1099-1069</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40397075</article-id><article-id pub-id-type="pmc">PMC12094220</article-id>
<article-id pub-id-type="doi">10.1002/hon.70104</article-id><article-id pub-id-type="publisher-id">HON70104</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Clustering Based on Innate Immunity Reveals Differential Dysregulation Based on Disease Severity in Myelodysplastic Neoplasms</article-title></title-group><contrib-group><contrib id="hon70104-cr-0001" contrib-type="author" corresp="yes"><name><surname>Passos</surname><given-names>Pedro Robson Costa</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0007-9049-0996</contrib-id><xref rid="hon70104-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="hon70104-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>pedropassos@alu.ufc.br</email></address></contrib><contrib id="hon70104-cr-0002" contrib-type="author"><name><surname>Vieira</surname><given-names>Andr&#x000e9;a Alc&#x000e2;ntara</given-names></name><xref rid="hon70104-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="hon70104-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="hon70104-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="hon70104-cr-0003" contrib-type="author"><name><surname>de Melo</surname><given-names>Renata Pinheiro Martins</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0009-7381-4914</contrib-id><xref rid="hon70104-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="hon70104-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="hon70104-cr-0004" contrib-type="author"><name><surname>Pinheiro Filho</surname><given-names>Ronald Feitosa</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5556-5274</contrib-id><xref rid="hon70104-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="hon70104-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="hon70104-cr-0005" contrib-type="author"><name><surname>Sampaio</surname><given-names>Leonardo Guimar&#x000e3;es</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0005-9759-0020</contrib-id><xref rid="hon70104-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="hon70104-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="hon70104-cr-0006" contrib-type="author"><name><surname>dos Santos</surname><given-names>Hermano Vinnicius Gomes</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0008-4186-977X</contrib-id><xref rid="hon70104-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="hon70104-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="hon70104-cr-0007" contrib-type="author"><name><surname>Sampaio</surname><given-names>Let&#x000ed;cia Rodrigues</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5784-3135</contrib-id><xref rid="hon70104-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="hon70104-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="hon70104-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="hon70104-cr-0008" contrib-type="author"><name><surname>Goes</surname><given-names>Jo&#x000e3;o Victor Caetano</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8933-145X</contrib-id><xref rid="hon70104-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="hon70104-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="hon70104-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="hon70104-cr-0009" contrib-type="author"><name><surname>Magalh&#x000e3;es</surname><given-names>S&#x000ed;lvia Maria Meira</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0001-2285-3026</contrib-id><xref rid="hon70104-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="hon70104-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="hon70104-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="hon70104-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="hon70104-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="hon70104-cr-0010" contrib-type="author"><name><surname>Pinheiro</surname><given-names>Ronald Feitosa</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3546-0974</contrib-id><xref rid="hon70104-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="hon70104-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="hon70104-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="hon70104-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="hon70104-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib></contrib-group><aff id="hon70104-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Laboratory of Cancer Cytogenetics</named-content>
<institution>Federal University of Cear&#x000e1;</institution>
<city>Fortaleza</city>
<country country="BR">Brazil</country>
</aff><aff content-type="private-address" id="hon70104-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>Research Center for Drug Development (NPDM)</institution>
<city>Fortaleza</city>
<country country="BR">Brazil</country>
</aff><aff content-type="private-address" id="hon70104-aff-0003">
<label>
<sup>3</sup>
</label>
<institution>Postgraduate Program in Medical Sciences</institution>
<institution>Federal University of Cear&#x000e1;</institution>
<city>Fortaleza</city>
<country country="BR">Brazil</country>
</aff><aff content-type="private-address" id="hon70104-aff-0004">
<label>
<sup>4</sup>
</label>
<institution>Postgraduate Program in Pathology</institution>
<institution>Federal University of Cear&#x000e1;</institution>
<city>Fortaleza</city>
<country country="BR">Brazil</country>
</aff><aff id="hon70104-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Department of Clinical Medicine</named-content>
<institution>Federal University of Cear&#x000e1;</institution>
<city>Fortaleza</city>
<country country="BR">Brazil</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence:</bold> Pedro Robson Costa Passos<break/>
(<email>pedropassos@alu.ufc.br</email>)<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>21</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2025</year></pub-date><volume>43</volume><issue seq="36">3</issue><issue-id pub-id-type="doi">10.1002/hon.v43.3</issue-id><elocation-id>e70104</elocation-id><history>
<date date-type="rev-recd"><day>17</day><month>3</month><year>2025</year></date>
<date date-type="received"><day>04</day><month>1</month><year>2025</year></date>
<date date-type="accepted"><day>09</day><month>5</month><year>2025</year></date>
</history><permissions><!--&#x000a9; 2025 John Wiley & Sons Ltd.--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">Hematological Oncology</italic> published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:HON-43-e70104.pdf"/><abstract><title>ABSTRACT</title><p>Myelodysplastic neoplasms (MDS) are clonal hematologic disorders characterized by ineffective hematopoiesis and a variable risk of progression to acute myeloid leukemia (AML). Despite growing recognition of the role of innate immunity in MDS pathogenesis, the precise mechanisms remain unclear. In this study, we analyzed bone marrow CD34+ expression data from 183 MDS patients to investigate the impact of the Toll&#x02010;like receptor (TLR) pathway on disease progression. Six key innate immunity genes (<italic toggle="yes">IRAK1</italic>, <italic toggle="yes">IRAK2</italic>, <italic toggle="yes">IRAK4</italic>, <italic toggle="yes">MYD88</italic>, <italic toggle="yes">TRAF6</italic>, and <italic toggle="yes">NFKB1</italic>) were used to define two distinct immune clusters: a hyperactive immune cluster (HIC) and a moderate immune cluster (MIC). The HIC was enriched in 155 immune&#x02010;related pathways and showed higher infiltration of activated natural killer cells and M1 macrophages, while the MIC exhibited increased infiltration of na&#x000ef;ve B cells and mast cells. Differential expression analysis identified 35 genes that distinguished the clusters. Validation in an independent cohort of 82 patients revealed that reduced expression of these genes correlated with markers of advanced disease, including lower hemoglobin levels, lower neutrophil counts, altered cytogenetics, and higher bone marrow blast percentages. These findings underscore the critical role of immune dysregulation in MDS progression and highlight novel therapeutic opportunities within the innate immunity pathway for tailored interventions.</p></abstract><kwd-group><kwd id="hon70104-kwd-0001">gene expression</kwd><kwd id="hon70104-kwd-0002">innate immunity</kwd><kwd id="hon70104-kwd-0003">irak kinases</kwd><kwd id="hon70104-kwd-0004">myelodysplastic syndromes</kwd><kwd id="hon70104-kwd-0005">toll&#x02010;like receptor</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>Brazilian Ministry of Science and Technology</funding-source></award-group><award-group id="funding-0002"><funding-source>National Council for Scientific and Technological Development</funding-source></award-group><award-group id="funding-0003"><funding-source>UNIVERSAL CNPq/MCTI/FNDCT N&#x000ba; 18/2021 &#x02010; Faixa B &#x02010; Grupos Consolidados</funding-source><award-id>#422726/2021&#x02010;4</award-id></award-group><award-group id="funding-0004"><funding-source>Novas tecnologias em Biotecnologia</funding-source><award-id>#440389/2022&#x02010;4</award-id></award-group><award-group id="funding-0005"><funding-source>Instituto Nacional de Ci&#x000ea;ncia e Tecnologia do Sangue</funding-source><award-id>#405918/2022&#x02010;4</award-id></award-group><award-group id="funding-0006"><funding-source>National Program for Support to Oncology Care</funding-source><award-id>#25000.019172/2021&#x02010;11</award-id></award-group><award-group id="funding-0007"><funding-source>Chamada CNPq N&#x000ba; 4/2021 &#x02010; Bolsas de Produtividade em Pesquisa &#x02010; PQ</funding-source><award-id>#307142/2021&#x02010;3</award-id></award-group></funding-group><counts><fig-count count="5"/><table-count count="0"/><page-count count="10"/><word-count count="6224"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>May 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.6 mode:remove_FC converted:21.05.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group><fn id="hon70104-note-0001"><p>
<bold>Funding:</bold> This research was funded by the Brazilian Ministry of Science and Technology supported by National Council for Scientific and Technological Development (CNPq) entitled: &#x0201c;UNIVERSAL CNPq/MCTI/FNDCT N&#x000ba; 18/2021 &#x02010; Faixa B &#x02010; Grupos Consolidados &#x02010; GRANT NUMBER #422726/2021&#x02010;4 &#x02010; An&#x000e1;lise da via STING de pacientes com S&#x000ed;ndrome Mielodispl&#x000e1;sica prim&#x000e1;ria e de modelos de les&#x000e3;o de fita dupla de DNA secund&#x000e1;ria a quimioter&#x000e1;picos em pacientes oncol&#x000f3;gicos e camundongos C57BL/6&#x0201d;; &#x0201c;CHAMADA CNPQ/MCTI/CT&#x02010;BIOTEC No 30/2022 &#x02010; Linha 2: Novas tecnologias em Biotecnologia &#x02010; GRANT NUMBER #440389/2022&#x02010;4 &#x02010; Desenvolvimento de linhagens geneticamente modificadas por crispr/cas9 com perda de fun&#x000e7;&#x000e3;o do gene TP53: induzindo o fen&#x000f3;tipo de instabilidade gen&#x000f4;mica da Neoplasia Mielodispl&#x000e1;sica (SMD)&#x0201d;; &#x0201c;Instituto Nacional de Ci&#x000ea;ncia e Tecnologia do Sangue (INCT do Sangue) / GRANT NUMBER #405918/2022&#x02010;4&#x0201d;; National Program for Support to Oncology Care (PRONON) &#x02010; GRANT NUMBER #25000.019172/2021&#x02010;11; Ronald Feitosa Pinheiro is recipient of a CNPq Research Productivity Scholarship &#x02010; Level 2 (Project: Chamada CNPq N&#x000ba; 4/2021 &#x02010; Bolsas de Produtividade em Pesquisa &#x02010; PQ, GRANT NUMBER #307142/2021&#x02010;3).</p></fn><fn fn-type="equal" id="hon70104-note-0002"><p>The first two authors contributed equally to this article.</p></fn></fn-group></notes></front><body id="hon70104-body-0001"><def-list list-content="abbreviations" id="hon70104-dl-0001"><title>Abbreviations</title><def-item><term>AML</term><def><p>Acute Myeloid Leukemia</p></def></def-item><def-item><term>AML&#x02010;RM</term><def><p>Acute Myeloid Leukemia Related to Myelodysplasia</p></def></def-item><def-item><term>BMPCs</term><def><p>Bone Marrow Pooled Cells</p></def></def-item><def-item><term>Cq</term><def><p>Quantification Cycle</p></def></def-item><def-item><term>DEGs</term><def><p>Differentially Expressed Genes</p></def></def-item><def-item><term>GSEA</term><def><p>Gene Set Enrichment Analysis</p></def></def-item><def-item><term>HIC</term><def><p>Hyperactive Immune Cluster</p></def></def-item><def-item><term>HSPC</term><def><p>Hematopoietic Stem and Progenitor Cells</p></def></def-item><def-item><term>IL</term><def><p>Interleukin</p></def></def-item><def-item><term>IRAK</term><def><p>Interleukin&#x02010;1 Receptor&#x02010;Associated Kinase</p></def></def-item><def-item><term>KEGG</term><def><p>Kyoto Encyclopedia of Genes and Genomes</p></def></def-item><def-item><term>MDS</term><def><p>Myelodysplastic Neoplasms</p></def></def-item><def-item><term>MIC</term><def><p>Moderate Immune Cluster</p></def></def-item><def-item><term>NF&#x02010;&#x003ba;B</term><def><p>Nuclear Factor kappa B</p></def></def-item><def-item><term>TLR</term><def><p>Toll&#x02010;Like Receptor</p></def></def-item></def-list><sec id="hon70104-sec-0010"><label>1</label><title>Introduction</title><p>Myelodysplastic neoplasms (MDS) constitute a heterogeneous group of clonal hematologic disorders characterized by ineffective hematopoiesis and an increased risk of acute myeloid leukemia (AML). The pathogenesis of MDS is linked to recurrent somatic mutations, resulting in the displacement of normal hematopoietic stem and progenitor cells (HSPCs) by their clonal counterparts [<xref rid="hon70104-bib-0001" ref-type="bibr">1</xref>, <xref rid="hon70104-bib-0002" ref-type="bibr">2</xref>, <xref rid="hon70104-bib-0003" ref-type="bibr">3</xref>]. Although the clonal dominance of MDS HSPCs has already been well elucidated, the mechanisms driving this phenomenon remain uncertain [<xref rid="hon70104-bib-0004" ref-type="bibr">4</xref>, <xref rid="hon70104-bib-0005" ref-type="bibr">5</xref>]. Mutations associated with clonal hematopoiesis and MDS are increasingly recognized in earlier stages of life, raising questions about their sufficiency in disease development [<xref rid="hon70104-bib-0006" ref-type="bibr">6</xref>, <xref rid="hon70104-bib-0007" ref-type="bibr">7</xref>]. This has shifted some of the focus toward understanding the selection mechanisms rather than the initial development of mutated HSPCs [<xref rid="hon70104-bib-0002" ref-type="bibr">2</xref>]. The inflammatory profile of the bone marrow microenvironment has emerged as a selective pressure influencing the survival and expansion of these clonal populations [<xref rid="hon70104-bib-0002" ref-type="bibr">2</xref>, <xref rid="hon70104-bib-0003" ref-type="bibr">3</xref>, <xref rid="hon70104-bib-0004" ref-type="bibr">4</xref>, <xref rid="hon70104-bib-0005" ref-type="bibr">5</xref>].</p><p>MDS HSPCs exhibit a unique innate immune response, with more than 50% of patients showing mutations and gene overexpression related to innate immune pathways [<xref rid="hon70104-bib-0005" ref-type="bibr">5</xref>, <xref rid="hon70104-bib-0008" ref-type="bibr">8</xref>]. This leads to heightened inflammatory signaling characterized by increased levels of cytokines, chemokines, microbial signals, and alarmins [<xref rid="hon70104-bib-0005" ref-type="bibr">5</xref>]. While inflammation typically impairs HSPC self&#x02010;renewal in chronic infections [<xref rid="hon70104-bib-0009" ref-type="bibr">9</xref>], in MDS, it plays a dual role by both contributing to bone marrow failure through HSPC cycling and promoting a proliferative phenotype that benefits clonal expansion [<xref rid="hon70104-bib-0002" ref-type="bibr">2</xref>, <xref rid="hon70104-bib-0003" ref-type="bibr">3</xref>, <xref rid="hon70104-bib-0004" ref-type="bibr">4</xref>, <xref rid="hon70104-bib-0005" ref-type="bibr">5</xref>, <xref rid="hon70104-bib-0010" ref-type="bibr">10</xref>]. MDS HSPCs are also known to overexpress toll&#x02010;like receptors (TLRs), particularly TLR2 and TLR4, and generate mutated macrophages that have increased NOD&#x02010;like receptor protein 3 inflammasome activation and interleukin (IL) 1 beta production, triggering the noncanonical nuclear factor kappa B (NF&#x02010;&#x003ba;B) pathway [<xref rid="hon70104-bib-0002" ref-type="bibr">2</xref>, <xref rid="hon70104-bib-0003" ref-type="bibr">3</xref>, <xref rid="hon70104-bib-0011" ref-type="bibr">11</xref>]. We previously demonstrated a positive correlation between interleukin 8 (IL&#x02010;8) and NF&#x02010;&#x003ba;B levels in MDS patients, suggesting that NF&#x02010;&#x003ba;B may drive IL&#x02010;8 expression and contribute to the inflammatory environment [<xref rid="hon70104-bib-0012" ref-type="bibr">12</xref>].</p><p>Despite promising results from preclinical studies targeting innate immunity in MDS [<xref rid="hon70104-bib-0013" ref-type="bibr">13</xref>], gaps remain in understanding how the TLR and NF&#x02010;&#x003ba;B pathways are related to MDS pathogenesis. While TLRs have been extensively studied, comprehensive investigations focusing on downstream signaling factors crucial for elucidating how they affect prognosis are lacking [<xref rid="hon70104-bib-0011" ref-type="bibr">11</xref>, <xref rid="hon70104-bib-0014" ref-type="bibr">14</xref>]. It is also unclear if any of the underexplored immunity&#x02010;related genes may serve as effective targets for inducing pro&#x02010;apoptotic phenotypes [<xref rid="hon70104-bib-0003" ref-type="bibr">3</xref>, <xref rid="hon70104-bib-0015" ref-type="bibr">15</xref>]. To address these gaps, we analyzed how clinical and molecular data from MDS patients were affected by innate immunity dysregulation.</p></sec><sec id="hon70104-sec-0020"><label>2</label><title>Subjects and Methods</title><sec id="hon70104-sec-0030"><label>2.1</label><title>Ethical Approval</title><p>The study received approval from the local ethics committee (process N&#x000ba; 76021523.2.0000.5054).</p></sec><sec id="hon70104-sec-0040"><label>2.2</label><title>Data Sources</title><p>We first analyzed data from the GSE19429 dataset available in the NCBI Gene Expression Omnibus (GEO) database, which includes mRNA expression data from the bone marrow CD34+ cells of 183 MDS patients. We subsequently examined samples collected from two reference Brazilian hospitals. This in&#x02010;house cohort aimed to address the limitations of the GSE19429 dataset, which lacked key disease&#x02010;specific parameters. Our cohort included 82 individuals: 76 diagnosed with MDS and 6 with acute myeloid leukemia myelodysplasia&#x02010;related (AML&#x02010;MR). For this group, we examined the mRNA expression data of bone marrow pooled cells (BNPCs) samples, along with peripheral blood, cytogenetic parameters, and bone marrow biopsy. For the characteristics of the in&#x02010;house cohort, see Supporting Information S1: Table&#x000a0;<xref rid="hon70104-sup-0001" ref-type="supplementary-material">S1</xref>. Given the extensive research on TLRs, we directed our attention to six pivotal downstream signaling genes: <italic toggle="yes">NFKB1</italic>, <italic toggle="yes">TRAF6</italic>, <italic toggle="yes">MYD88</italic>, <italic toggle="yes">IRAK1</italic>, <italic toggle="yes">IRAK2</italic>, and <italic toggle="yes">IRAK4</italic>.</p></sec><sec id="hon70104-sec-0050"><label>2.3</label><title>Clustering Analysis</title><p>Using data from GSE19429, we utilized the &#x0201c;ConsensusClusterPlus&#x0201d; package from R software to assess the ideal number of clusters and then performed k&#x02010;means clustering on log2&#x02010;transformed gene expression data of our six assessed genes (<italic toggle="yes">NFKB1</italic>, <italic toggle="yes">TRAF6</italic>, <italic toggle="yes">MYD88</italic>, <italic toggle="yes">IRAK1</italic>, <italic toggle="yes">IRAK2</italic>, and <italic toggle="yes">IRAK4</italic>).</p></sec><sec id="hon70104-sec-0060"><label>2.4</label><title>Differentially Expressed Genes and Gene Set Enrichment Analysis</title><p>Differentially expressed genes (DEGs) were screened between the clusters (FDR&#x000a0;&#x0003c;&#x000a0;0.05, |log<sub>2</sub>FC|&#x000a0;&#x02265;&#x000a0;1). Protein&#x02010;protein interactions (PPI) between their products were assessed using the string database (<ext-link xlink:href="https://www.string-db.org/" ext-link-type="uri">https://www.string&#x02010;db.org/</ext-link>). We conducted gene&#x02010;set enrichment analysis (GSEA) between the clusters to identify which pathways are differentially functional between the groups. A Reactome pathway analysis was used to explore the TLR pathway, complemented by Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses to investigate additional pathways of interest [<xref rid="hon70104-bib-0016" ref-type="bibr">16</xref>, <xref rid="hon70104-bib-0017" ref-type="bibr">17</xref>]. The R package &#x0201c;clusterProfiler&#x0201d; was used to screen for KEGG pathways (NES|&#x000a0;&#x0003e;&#x000a0;1, Nom <italic toggle="yes">p</italic>&#x02010;value&#x02009;&#x000a0;&#x0003c;&#x000a0;&#x02009;0.05).</p></sec><sec id="hon70104-sec-0070"><label>2.5</label><title>Immune Infiltration Estimation</title><p>The CIBERSORT gene signature (<ext-link xlink:href="http://cibersort.stanford.edu/" ext-link-type="uri">http://cibersort.stanford.edu/</ext-link>) was used to infer immune cell types in the selected clusters. This feature employs a computational approach that accurately resolves relative fractions of diverse cell subsets in gene expression profiles from complex tissue. The scores of infiltrating immune cells were calculated using this method, enabling an in&#x02010;depth analysis of the tumor microenvironment [<xref rid="hon70104-bib-0018" ref-type="bibr">18</xref>].</p></sec><sec id="hon70104-sec-0080"><label>2.6</label><title>Cytogenetic Analysis</title><p>Bone marrow was collected in heparin under sterile conditions and divided into two vials containing 7&#x000a0;mL of RPMI 1640 medium (pH 7.0), 3&#x000a0;mL of fetal bovine serum, and 100&#x000a0;&#x003bc;L of L&#x02010;glutamine. The material was cultured for 24&#x000a0;h in an incubator at 37&#x000b0;C with 5% CO<sub>2</sub>. Banding was performed via the trypsin technique, and the bands were stained with Giemsa [<xref rid="hon70104-bib-0019" ref-type="bibr">19</xref>]. At least 20 metaphases from each patient were analyzed via a computerized system with CytoVision software. The results were reported according to the International System for Human Cytogenomic Nomenclature (ISCN) criteria.</p></sec><sec id="hon70104-sec-0090"><label>2.7</label><title>Real Time RT&#x02010;PCR</title><p>Total cellular RNA was extracted from BNPCs of patients with MDS and AML&#x02010;RM via TRIzol (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol. cDNA synthesis was performed via the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA) following the manufacturer's recommendations. The quantification of gene expression was performed via real&#x02010;time PCR on a 7500 Real&#x02010;Time PCR System (Applied Biosystems, Carlsbad, CA). Three reference genes (<italic toggle="yes">ACTB</italic>, <italic toggle="yes">GAPDH</italic>, <italic toggle="yes">HPRT1</italic>) were identified via the online tool RefFinder (<ext-link xlink:href="https://www.heartcure.com.au/reffinder/" ext-link-type="uri">https://www.heartcure.com.au/reffinder/</ext-link>). Results were evaluated via Sequence Detection System v1.3 software (Applied Biosystems, Carlsbad, CA) to obtain quantitative cycle (Cq) values. We then calculated the &#x00394;Cq values and 2<sup>&#x02212;&#x00394;Cq</sup> for both the target and reference genes.</p></sec><sec id="hon70104-sec-0100"><label>2.8</label><title>Statistical Analysis</title><p>For comparing gene expression values within different groups, we employed either Nonparametric Mann Whitney test or Kruskal&#x02010;Walles test with Dunn's post hoc tests, assuming the Bonferroni correction for multiple comparisons. For categorical variables, we employed the Chi&#x02010;squared test. For risk stratification in the in&#x02010;house cohort, patients with a revised International Prognostic Scoring System (IPSS&#x02010;R) classification of very low, low, or intermediate risk were categorized as having early&#x02010;stage disease, while those with high, very high risk, or AML&#x02010;MR were classified as having advanced&#x02010;stage disease. Statistical analyses were performed in R (version 4.3.2, R Foundation for Statistical Computing, Vienna, Austria), with two&#x02010;sided tests and a significance threshold of <italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.05.</p></sec></sec><sec id="hon70104-sec-0110"><label>3</label><title>Results</title><sec id="hon70104-sec-0120"><label>3.1</label><title>Clustering and Immune Infiltration</title><p>Consensus clustering of the expression patterns of six key genes (<italic toggle="yes">NFKB</italic>, <italic toggle="yes">TRAF6</italic>, <italic toggle="yes">MYD88</italic>, <italic toggle="yes">IRAK1</italic>, <italic toggle="yes">IRAK2</italic>, and <italic toggle="yes">IRAK4</italic>) identified an optimal number of clusters at <italic toggle="yes">k</italic>&#x000a0;=&#x000a0;2 (Figure&#x000a0;<xref rid="hon70104-fig-0001" ref-type="fig">1A&#x02010;C</xref>). 72 patients (39.3%) were grouped into a cluster characterized by elevated expression of <italic toggle="yes">NFKB1</italic>, <italic toggle="yes">TRAF6</italic>, <italic toggle="yes">MYD88</italic>, and <italic toggle="yes">IRAK4</italic>, designated as the &#x0201c;Hyperactive Immune Cluster&#x0201d; (HIC, Figure&#x000a0;<xref rid="hon70104-fig-0001" ref-type="fig">1D</xref>) due to its overexpression of four out of the six assessed genes. The remaining 111 patients (60.7%) were assigned to a cluster with increased expression of <italic toggle="yes">IRAK1</italic>, referred to as the &#x0201c;Moderate Immune Cluster&#x0201d; (MIC, Figure&#x000a0;<xref rid="hon70104-fig-0001" ref-type="fig">1D</xref>). No significant differences in chromosomal alterations or disease subtypes were observed between these clusters (<italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.326 and 0.346, respectively; Figure&#x000a0;<xref rid="hon70104-fig-0001" ref-type="fig">1E</xref>). Immune infiltration estimation analysis revealed that the HIC was enriched for M1 macrophages, resting myeloid dendritic cells, activated natural killer (NK) cells, and resting mast cells (<italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.020, 0.030, 0.005, and &#x0003c;&#x000a0;0.001, respectively), whereas the MIC showed higher levels of naive B cells, active mast cells, and resting NK cells (<italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.020, &#x0003c;&#x000a0;0.001, and &#x0003c;&#x000a0;0.001, respectively, Figure&#x000a0;<xref rid="hon70104-fig-0002" ref-type="fig">2A&#x02013;B</xref>).</p><fig position="float" fig-type="FIGURE" id="hon70104-fig-0001"><label>FIGURE 1</label><caption><p>Clustering&#x02010;based division of MDS patients based on innate immunity. [A] Consensus clustering analysis identified two distinct patient clusters. [B] Cumulative distribution function illustrating cluster stability across two to five clusters. [C] Relative changes in the area under the cumulative distribution function curve as the number of clusters increases. [D] Differential expression of six key genes across the identified clusters. [E] Integration of gene expression differences with chromosomal alterations, disease subtypes, and cluster assignments. CDF, consensus distribution function; HIC, hyperactive immune cluster; MIC, moderate immune cluster.</p></caption><graphic xlink:href="HON-43-e70104-g005" position="anchor" id="jats-graphic-1"/></fig><fig position="float" fig-type="FIGURE" id="hon70104-fig-0002"><label>FIGURE 2</label><caption><p>Immune assessment by CIBERSORT deconvolution within MDS patients. [A] Mapping of the distributions of immune cell&#x02010;related scores stratified by cluster assignment. [B] Significant differences of immune cell expression between clusters. HIC, hyperactive immune cluster; MIC, moderate immune cluster; NK, natural killer.</p></caption><graphic xlink:href="HON-43-e70104-g001" position="anchor" id="jats-graphic-3"/></fig></sec><sec id="hon70104-sec-0130"><label>3.2</label><title>Pathway Assessment</title><p>GSEA identified 155 enriched pathways in the HIC compared to the MIC. Figure&#x000a0;<xref rid="hon70104-fig-0003" ref-type="fig">3A</xref> displays the top 25 enriched pathways. The HIC demonstrated significant enrichment in pathways relevant to MDS and innate immunity: the TLR pathway (normalized enrichment score [NES]&#x000a0;=&#x000a0;2.42, <italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.001, Figure&#x000a0;<xref rid="hon70104-fig-0003" ref-type="fig">3B</xref>), hematopoietic cell lineage (NES&#x000a0;=&#x000a0;1.80, <italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.001, Figure <xref rid="hon70104-fig-0003" ref-type="fig">3B</xref>), the apoptotic signaling pathway (NES&#x000a0;=&#x000a0;1.97, <italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.001, Figure <xref rid="hon70104-fig-0003" ref-type="fig">3B</xref>), cytokine&#x02010;cytokine receptor interaction (NES&#x000a0;=&#x000a0;1.93, <italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.001, Figure <xref rid="hon70104-fig-0003" ref-type="fig">3B</xref>), NK cell&#x02010;mediated cytotoxicity (NES&#x000a0;=&#x000a0;1.71, <italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.001, Figure <xref rid="hon70104-fig-0003" ref-type="fig">3B</xref>), and antigen processing and presentation (NES&#x000a0;=&#x000a0;1.55, <italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.012, Figure <xref rid="hon70104-fig-0003" ref-type="fig">3B</xref>).</p><fig position="float" fig-type="FIGURE" id="hon70104-fig-0003"><label>FIGURE 3</label><caption><p>Gene set enrichment analysis of the hyperactive immune cluster in comparison to the moderate immune cluster. [A] Top 25 enriched pathways in the hyperactive immune cluster, ranked by normalized enrichment score. [B] Normalized enrichment score and nominal <italic toggle="yes">p</italic>&#x02010;value of key immune&#x02010;related pathways relevant to MDS. NES, normalized enrichment score; Nom <italic toggle="yes">p,</italic> nominal <italic toggle="yes">p</italic>&#x02010;value.</p></caption><graphic xlink:href="HON-43-e70104-g003" position="anchor" id="jats-graphic-5"/></fig></sec><sec id="hon70104-sec-0140"><label>3.3</label><title>Differentially&#x02010;Expressed Genes</title><p>We identified 35 DEGs between the two clusters, with only one gene, <italic toggle="yes">RPL31</italic>, showing higher expression in the MIC cluster (Figure <xref rid="hon70104-fig-0004" ref-type="fig">4A&#x02013;B</xref>). For specific adjusted <italic toggle="yes">p</italic>&#x02010;values and log fold&#x02010;change, see Supporting Information S1: Table&#x000a0;<xref rid="hon70104-sup-0001" ref-type="supplementary-material">S2</xref>. PPI analysis revealed significant interactions among the DEGs (Figure&#x000a0;<xref rid="hon70104-fig-0004" ref-type="fig">4C</xref>).</p><fig position="float" fig-type="FIGURE" id="hon70104-fig-0004"><label>FIGURE 4</label><caption><p>Differentially expressed gene analysis between the clusters. [A] Volcano plot highlighting differentially expressed genes filtered by <italic toggle="yes">p</italic>&#x02010;value&#x000a0;&#x0003c;&#x000a0;0.05 and Log<sub>2</sub>(Fold Change)&#x000a0;&#x0003e;&#x000a0;1. [B] Cluster&#x02010;specific mapping of the identified differentially expressed genes. [C] Protein&#x02010;protein interaction network showing known interactions among proteins encoded by the differentially expressed genes. FC, fold change, NS, non&#x02010;significant.</p></caption><graphic xlink:href="HON-43-e70104-g002" position="anchor" id="jats-graphic-7"/></fig></sec><sec id="hon70104-sec-0150"><label>3.4</label><title>Peripheral Blood Parameters</title><p>Patients from the in&#x02010;house cohort were split into groups for gene expression analysis on the basis of the IPSS&#x02010;R thresholds for hemoglobin (&#x0003c;&#x000a0;8&#x000a0;g/dL, 8&#x02013;10&#x000a0;g/dL, and &#x0003e;&#x000a0;10&#x000a0;g/dL), absolute neutrophil count (ANC; &#x0003c;&#x000a0;800&#x000a0;mm<sup>3</sup> and &#x02265;&#x000a0;800&#x000a0;mm<sup>3</sup>), and platelet count (&#x0003c;&#x000a0;50,000; 50,000 &#x02010;&#x000a0;&#x0003c;&#x000a0;100,000; and &#x02265;&#x000a0;100,000). Patients with hemoglobin levels below 8&#x000a0;g/dL had lower <italic toggle="yes">MYD88</italic> expression than did those with levels above 10&#x000a0;g/dL (<italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.039; Figure&#x000a0;<xref rid="hon70104-fig-0005" ref-type="fig">5A</xref>). Early disease (see methods for definition) patients maintained this trend (<italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.027, Figure&#x000a0;<xref rid="hon70104-fig-0005" ref-type="fig">5B</xref>). Individuals within early disease with ANC of &#x0003c;&#x000a0;800&#x000a0;mm<sup>3</sup> had significantly higher expression of both <italic toggle="yes">MYD88</italic> and <italic toggle="yes">TRAF6</italic> when compared to those with &#x02265;&#x000a0;800&#x000a0;mm<sup>3</sup> (<italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.019 and <italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.050, respectively, Figure&#x000a0;<xref rid="hon70104-fig-0005" ref-type="fig">5C&#x02013;D</xref>). Advanced disease patients with ANC of &#x0003c;&#x000a0;800&#x000a0;mm<sup>3</sup> overexpressed <italic toggle="yes">IRAK4</italic> when compared to patients with &#x02265;&#x000a0;800&#x000a0;mm<sup>3</sup> (<italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.029, Figure&#x000a0;<xref rid="hon70104-fig-0005" ref-type="fig">5E</xref>).</p><fig position="float" fig-type="FIGURE" id="hon70104-fig-0005"><label>FIGURE 5</label><caption><p>Significant associations among surrogate outcomes of advanced disease by expression of six key genes in the in&#x02010;house cohort. [A], [F], [G], [H], [I], and [J] represent analyses conducted across all patients. [B], [C], [D], and [K] focus on early disease patients, while [E] examines advanced disease patients. Comparisons involving more than three factors were analyzed using the Kruskal&#x02010;Wallis test with Dunn's post&#x02010;hoc adjustment. Comparisons between two factors were performed using the Wilcoxon test. AML&#x02010;MR, acute myeloid leukemia myelodysplasia&#x02010;related; MDS&#x02010;del5a, myelodysplastic neoplasm with deletion of 5q; MDS&#x02010;h, hypoplastic myelodysplastic neoplasm; MDS&#x02010;IB1, myelodysplastic neoplasm with increased blasts 1; MDS&#x02010;IB2, myelodysplastic neoplasm with increased blasts 2; MDS&#x02010;LB, myelodysplastic neoplasms with low blasts; MDS&#x02010;LB&#x02010;RS, myelodysplastic syndromes with low blasts and ring sideroblasts.</p></caption><graphic xlink:href="HON-43-e70104-g004" position="anchor" id="jats-graphic-9"/></fig></sec><sec id="hon70104-sec-0160"><label>3.5</label><title>Bone Marrow Parameters</title><p>Patients from the in&#x02010;house cohort were grouped by blast percentage using IPSS&#x02010;R thresholds: &#x02264;&#x000a0;2%, &#x0003e;&#x000a0;2% &#x02013; &#x0003c;&#x000a0;5%, 5%&#x02013;10%, and &#x0003e;&#x000a0;10%. <italic toggle="yes">NFKB1</italic> expression was significantly lower in patients with &#x02264;&#x000a0;2% blasts than those with &#x0003e;&#x000a0;2 &#x02013; &#x0003c;&#x000a0;5% (<italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.042, Figure&#x000a0;<xref rid="hon70104-fig-0005" ref-type="fig">5F</xref>). <italic toggle="yes">MYD88</italic> expression was significantly lower in patients with &#x0003e;&#x000a0;10% blasts than in those with &#x02264;&#x000a0;2%, blasts (<italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.027; Figure&#x000a0;<xref rid="hon70104-fig-0005" ref-type="fig">5G</xref>). <italic toggle="yes">IRAK1</italic> expression was lower in patients with &#x0003e;&#x000a0;10% blasts than in those with 5%&#x02013;10% blasts (<italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.034; Figure&#x000a0;<xref rid="hon70104-fig-0005" ref-type="fig">5H</xref>). For <italic toggle="yes">IRAK2</italic>, patients with &#x0003e; 10% blasts had reduced expression relative to those with &#x02264;&#x000a0;2% blasts (<italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.002; Figure&#x000a0;<xref rid="hon70104-fig-0005" ref-type="fig">5I</xref>). No significant associations were observed between gene expression and dyserythropoiesis, dysmegakaryopoiesis, or dysgranulopoiesis (See Supporting Information S1: Table&#x000a0;<xref rid="hon70104-sup-0001" ref-type="supplementary-material">S3</xref>).</p></sec><sec id="hon70104-sec-0170"><label>3.6</label><title>Disease Subtype</title><p>We selected disease subtypes with more than one patient in our cohort for this analysis. All were classified on the basis of the 5th edition of the World Health Organization Classification of Haematolymphoid Tumors [<xref rid="hon70104-bib-0020" ref-type="bibr">20</xref>]. Our analysis revealed that <italic toggle="yes">MYD88</italic> expression was significantly greater in AML&#x02010;RM patients than in MDS&#x02010;LB patients (<italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.046, Figure&#x000a0;<xref rid="hon70104-fig-0005" ref-type="fig">5J</xref>).</p></sec><sec id="hon70104-sec-0180"><label>3.7</label><title>Cytogenetic Parameters</title><p>Patients from the in&#x02010;house cohort were grouped both by cytogenetic results (normal, altered non&#x02010;complex, and complex) and using IPSS&#x02010;R classifications, with those with very good, good or intermediate prognostic value being classified as low cytogenetic risk, and those with bad or very bad risk being classified as high cytogenetic risk. The only significant association was seen in early disease patients, in which those with normal cytogenetics had higher <italic toggle="yes">IRAK1</italic> expression when compared to those with altered non&#x02010;complex cytogenetics (<italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.030, Figure&#x000a0;<xref rid="hon70104-fig-0005" ref-type="fig">5K</xref>).</p></sec></sec><sec id="hon70104-sec-0190"><label>4</label><title>Discussion</title><p>Altered expression across various levels of innate immune signaling drives distinct biological effects in MDS [<xref rid="hon70104-bib-0011" ref-type="bibr">11</xref>, <xref rid="hon70104-bib-0021" ref-type="bibr">21</xref>, <xref rid="hon70104-bib-0022" ref-type="bibr">22</xref>]. Low&#x02010;risk MDS is characterized by a hyperimmune state, with increased cytotoxic T lymphocyte and helper T cell 17 targeting MHC&#x02010;class I molecules on HSPCs, longside a significant decrease in regulatory T cells that facilitates the apoptosis of mutated HSPCs [<xref rid="hon70104-bib-0015" ref-type="bibr">15</xref>, <xref rid="hon70104-bib-0023" ref-type="bibr">23</xref>]. This activation is often driven by the NF&#x02010;&#x003ba;B pathway through overexpression of activators like TLR2 and TLR4 and downregulation of inhibitors such as miR145 and miR146a [<xref rid="hon70104-bib-0003" ref-type="bibr">3</xref>, <xref rid="hon70104-bib-0023" ref-type="bibr">23</xref>, <xref rid="hon70104-bib-0024" ref-type="bibr">24</xref>, <xref rid="hon70104-bib-0025" ref-type="bibr">25</xref>]. In contrast, high&#x02010;risk MDS is typically associated with an anti&#x02010;apoptotic phenotype, with upregulation of the anti&#x02010;apoptotic protein Bcl&#x02010;2 and a reduction in apoptotic cell markers like Apo2.7 in CD34+ cells [<xref rid="hon70104-bib-0015" ref-type="bibr">15</xref>, <xref rid="hon70104-bib-0026" ref-type="bibr">26</xref>]. In our analysis, the HIC exhibited an enrichment of apoptosis&#x02010;related pathways, along with a heightened NK cell activity, an increase in M1 macrophages, differential upregulation of immune&#x02010;related genes, and enrichment of various immune pathways compared to the MIC, consistent with features associated with low&#x02010;risk MDS [<xref rid="hon70104-bib-0003" ref-type="bibr">3</xref>, <xref rid="hon70104-bib-0021" ref-type="bibr">21</xref>, <xref rid="hon70104-bib-0023" ref-type="bibr">23</xref>, <xref rid="hon70104-bib-0027" ref-type="bibr">27</xref>, <xref rid="hon70104-bib-0028" ref-type="bibr">28</xref>, <xref rid="hon70104-bib-0029" ref-type="bibr">29</xref>]. In this sense, HIC's immune activation may enhance early disease surveillance but also contribute to bone marrow failure. Conversely, the MIC phenotype may reflect late immune exhaustion or suppression, potentially facilitating disease progression and resistance to certain immunotherapies.</p><p>Stratifying the MDS spectrum is helpful for assessing target populations for novel treatment. Preclinical studies have explored all of our assessed gene products with the exception of IRAK2 [<xref rid="hon70104-bib-0014" ref-type="bibr">14</xref>, <xref rid="hon70104-bib-0030" ref-type="bibr">30</xref>, <xref rid="hon70104-bib-0031" ref-type="bibr">31</xref>, <xref rid="hon70104-bib-0032" ref-type="bibr">32</xref>]. However, indirect NF&#x02010;&#x003ba;B targeting was the first to advance into human trials for MDS, with the proteasome inhibitor Bortezomib showing modest and variable response rates [<xref rid="hon70104-bib-0033" ref-type="bibr">33</xref>]. Inhibition of NF&#x02010;&#x003ba;B enhances apoptosis in MDS blast cells and is thought to play a critical role in the transition from high&#x02010;apoptotic to low&#x02010;apoptotic phenotypes [<xref rid="hon70104-bib-0027" ref-type="bibr">27</xref>]. The therapeutic effects of Myd88 and Traf6 inhibition are believed to stem from the counteracting of the anti&#x02010;apoptotic functions of NF&#x02010;&#x003ba;B [<xref rid="hon70104-bib-0014" ref-type="bibr">14</xref>, <xref rid="hon70104-bib-0034" ref-type="bibr">34</xref>]. Notably, the only trial targeting NF&#x02010;&#x003ba;B in MDS patients has focused on low&#x02010;risk patients [<xref rid="hon70104-bib-0033" ref-type="bibr">33</xref>], which may account for their only moderate outcomes, as the induction of apoptosis may have greater effects on anti&#x02010;apoptotic phenotypes [<xref rid="hon70104-bib-0030" ref-type="bibr">30</xref>]. IRAK4 inhibitors have also entered human trials, with Emavusertib, a selective IRAK4 inhibitor, currently being evaluated in the Phase 1/2 TakeAim Leukemia trial (NCT04278768), which has shown promising preliminary efficacy [<xref rid="hon70104-bib-0035" ref-type="bibr">35</xref>].</p><p>High <italic toggle="yes">MYD88</italic> expression has been paradoxically associated with both reduced overall survival and low&#x02010;risk disease in MDS patients [<xref rid="hon70104-bib-0014" ref-type="bibr">14</xref>]. Interestingly, inhibiting MYD88 in CD34+ cells of low&#x02010;risk MDS patients has been shown to increase erythroid colony formation [<xref rid="hon70104-bib-0014" ref-type="bibr">14</xref>]. Given the known dynamics between hyperimmuninity and hematopoiesis, <italic toggle="yes">MYD88</italic>&#x02010;enriched MDS link to HSPC dysfunction is likely due to chronic TLR signaling [<xref rid="hon70104-bib-0024" ref-type="bibr">24</xref>, <xref rid="hon70104-bib-0036" ref-type="bibr">36</xref>, <xref rid="hon70104-bib-0037" ref-type="bibr">37</xref>]. However, we found that higher hemoglobin levels were associated with increased <italic toggle="yes">MYD88</italic> expression, a trend that persisted when stratifying by early, but not advanced, disease. This pattern may indicate that <italic toggle="yes">MYD88</italic>&#x02010;based signaling predominates in the early stages of the disease, before HSPC dysfunction strongly impacts hemoglobin levels. Indeed, AML&#x02010;MR patients exhibited lower <italic toggle="yes">MYD88</italic> expression than MDS&#x02010;LB patients. <italic toggle="yes">MYD88</italic> is a potent stimulator of IL&#x02010;8, IL&#x02010;6, and IL&#x02010;1 signaling [<xref rid="hon70104-bib-0014" ref-type="bibr">14</xref>, <xref rid="hon70104-bib-0038" ref-type="bibr">38</xref>, <xref rid="hon70104-bib-0039" ref-type="bibr">39</xref>, <xref rid="hon70104-bib-0040" ref-type="bibr">40</xref>], which are implicated in chronic erythroid dysfunction [<xref rid="hon70104-bib-0012" ref-type="bibr">12</xref>, <xref rid="hon70104-bib-0041" ref-type="bibr">41</xref>, <xref rid="hon70104-bib-0042" ref-type="bibr">42</xref>, <xref rid="hon70104-bib-0043" ref-type="bibr">43</xref>, <xref rid="hon70104-bib-0044" ref-type="bibr">44</xref>]. Furthermore, because our analysis included BMPCs rather than isolated CD34+ cells, the observed effects might reflect <italic toggle="yes">MYD88'</italic>s broader influence on the hematopoietic niche. <italic toggle="yes">MYD88</italic> signaling influences macrophage differentiation, CD4+ T&#x02010;cell production of IFN&#x02010;&#x003b3;, and both early and late hematopoiesis [<xref rid="hon70104-bib-0045" ref-type="bibr">45</xref>, <xref rid="hon70104-bib-0046" ref-type="bibr">46</xref>, <xref rid="hon70104-bib-0047" ref-type="bibr">47</xref>, <xref rid="hon70104-bib-0048" ref-type="bibr">48</xref>, <xref rid="hon70104-bib-0049" ref-type="bibr">49</xref>].</p><p>Early disease patients with lower ANCs also exhibited <italic toggle="yes">MYD88</italic> overexpression. We hypothesize that reduced ANCs may drive <italic toggle="yes">MYD88</italic> overexpression rather than the reverse, as <italic toggle="yes">MYD88</italic> plays a critical role in facilitating TH1 differentiation in response to immune challenges [<xref rid="hon70104-bib-0046" ref-type="bibr">46</xref>, <xref rid="hon70104-bib-0050" ref-type="bibr">50</xref>], which these patients are more prone to. This could explain the increased mortality in <italic toggle="yes">MYD88</italic>&#x02010;enriched patients [<xref rid="hon70104-bib-0014" ref-type="bibr">14</xref>]. Of note, higher <italic toggle="yes">TRAF6</italic> expression was also linked to decreased ANCs in early disease patients. Although this may follow the mechanisms previously described, as <italic toggle="yes">TRAF6</italic> is an important downstream mediator of <italic toggle="yes">MYD88</italic> signaling, previous studies have shown that the loss of <italic toggle="yes">TIFAB</italic>, a gene associated with MDS&#x02010;del5q, results in increased TRAF6 levels and altered myeloid differentiation, including neutrophil dysplasia and cytopenia [<xref rid="hon70104-bib-0003" ref-type="bibr">3</xref>, <xref rid="hon70104-bib-0051" ref-type="bibr">51</xref>]. Furthermore, <italic toggle="yes">TRAF6</italic> overexpression is linked to the ubiquitination of hnRNPA1, which affects RNA processing and contributes to hematopoietic defects [<xref rid="hon70104-bib-0052" ref-type="bibr">52</xref>].</p><p>Research on IRAK expression in MDS remains limited, with most attention focused on <italic toggle="yes">IRAK4</italic>, whereas other IRAK family members have not been extensively evaluated [<xref rid="hon70104-bib-0053" ref-type="bibr">53</xref>, <xref rid="hon70104-bib-0054" ref-type="bibr">54</xref>]. We observed that <italic toggle="yes">IRAK1</italic> and <italic toggle="yes">IRAK2</italic> underexpression were associated with higher bone marrow blast percentages. This same effect was seen in <italic toggle="yes">MYD88</italic>, meaning that much of the pathway is underexpressed in this group, with the exception of <italic toggle="yes">NFKB1</italic>, in which overexpression correlated with high blast percentage. This exception is likely due to the dependency of blast survival and proliferation on an anti&#x02010;apoptotic environment [<xref rid="hon70104-bib-0055" ref-type="bibr">55</xref>, <xref rid="hon70104-bib-0056" ref-type="bibr">56</xref>]. <italic toggle="yes">IRAK1'</italic>s association in early disease with normal cytogenetics, a surrogate marker for overall survival and leukemic transformation in MDS [<xref rid="hon70104-bib-0057" ref-type="bibr">57</xref>, <xref rid="hon70104-bib-0058" ref-type="bibr">58</xref>], also reflects the protective role of hyperimmunity in preventing malignant transformation. Moreover, advanced disease patients with higher ANCs exhibited overexpression of <italic toggle="yes">IRAK4</italic>. Upon activation, <italic toggle="yes">IRAK4</italic> stimulates the production of pro&#x02010;inflammatory cytokines and chemokines [<xref rid="hon70104-bib-0059" ref-type="bibr">59</xref>, <xref rid="hon70104-bib-0060" ref-type="bibr">60</xref>, <xref rid="hon70104-bib-0061" ref-type="bibr">61</xref>]. Due to this, <italic toggle="yes">IRAK4</italic>&#x02010;inactive mouse models exhibit reduced inflammatory responses, including diminished neutrophil recruitment [<xref rid="hon70104-bib-0062" ref-type="bibr">62</xref>]. Therefore, IRAK4 inhibitors may adversely affect ANCs, particularly in high&#x02010;risk patients whose immune responses are already compromised [<xref rid="hon70104-bib-0015" ref-type="bibr">15</xref>]. Given that IRAK4 inhibitors have not yet been evaluated in high&#x02010;risk MDS, this raises a significant concern for their potential impact in this population.</p><p>This study has limitations that should be acknowledged. First, the in&#x02010;house cohort was derived from a single country, which may limit the generalizability of our results. Second, the use of BMPCs could obscure cell&#x02010;specific expression patterns, although this has shown to not significantly impact pathway analysis [<xref rid="hon70104-bib-0063" ref-type="bibr">63</xref>]. Third, the study did not include functional validation of the identified patterns, leaving the mechanistic implications to be inferred from correlative data. Fourth, the absence of a well&#x02010;defined low&#x02010;immune cluster reduces interpretability. Finally, we were unable to incorporate potentially relevant patient data, such as mutational profiles. In summary, the immune profiling described here could aid in refining MDS stratification, particularly in distinguishing patients who may benefit from immune&#x02010;modulating therapies such as IRAK4 inhibitors or NF&#x02010;&#x003ba;B&#x02010;targeting agents. Specifically, the enrichment of diverse immune&#x02010;related pathways in the HIC cluster suggests that these patients could be prime candidates for future immunotherapy strategies. Recent studies show that immune&#x02010;based stratification can accurately predict survival in MDS patients, with transcriptomic techniques paving the way for the integration of this tool in oncology [<xref rid="hon70104-bib-0018" ref-type="bibr">18</xref>, <xref rid="hon70104-bib-0052" ref-type="bibr">52</xref>, <xref rid="hon70104-bib-0064" ref-type="bibr">64</xref>, <xref rid="hon70104-bib-0065" ref-type="bibr">65</xref>]. However, most immune&#x02010;modulating therapies for MDS are still in the preclinical phase [<xref rid="hon70104-bib-0066" ref-type="bibr">66</xref>, <xref rid="hon70104-bib-0067" ref-type="bibr">67</xref>]. Future research should validate our insights and explore stratification for immune&#x02010;based target therapies in MDS.</p></sec><sec sec-type="COI-statement" id="hon70104-sec-0210"><title>Conflicts of Interest</title><p>The authors declare that they have no known competing financial interests or personal relationships that could have influenced the work reported in this paper.</p></sec><sec id="hon70104-sec-0220"><sec disp-level="2" id="hon70104-sec-0230"><title>Peer Review</title><p>The peer review history for this article is available at <ext-link xlink:href="https://www.webofscience.com/api/gateway/wos/peer-review/10.1002/hon.70104" ext-link-type="uri">https://www.webofscience.com/api/gateway/wos/peer-review/10.1002/hon.70104</ext-link>.</p></sec></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="hon70104-sup-0001" position="float" content-type="local-data"><caption><p>Supporting Information S1</p></caption><media xlink:href="HON-43-e70104-s001.docx"/></supplementary-material></sec></body><back><ack id="hon70104-sec-0200"><title>Acknowledgments</title><p>This research and draft were conducted only by the authors involved in the preparation and submission of the manuscript. P.R.C. Passos, L.G. Sampaio, R.P.M. Melo, R.F. Pinheiro Filho, and R.F. Pinheiro wrote the manuscript. P.R.C. Passos conducted the data analysis. A.A. Vieira, P.R.C. Passos, and R.F. Pinheiro designed the study. J.V. Goes, S.M. Meira Magalh&#x000e3;es, H.V. Gomes dos Santos, and L.R. Sampaio contributed significantly to the study design and provided essential support throughout the research process.</p></ack><sec sec-type="data-availability" id="hon70104-sec-0240"><title>Data Availability Statement</title><p>The data utilized in this study are accessible upon reasonable request to the corresponding author.</p></sec><ref-list content-type="cited-references" id="hon70104-bibl-0001"><title>References</title><ref id="hon70104-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="hon70104-cit-0001">
<string-name>
<given-names>M.</given-names>
<surname>Cazzola</surname>
</string-name>, &#x0201c;<article-title>Myelodysplastic Syndromes</article-title>,&#x0201d; <source>New England Journal of Medicine</source>
<volume>383</volume>, no. <issue>14</issue> (<year>October 2020</year>): <fpage>1358</fpage>&#x02013;<lpage>1374</lpage>, <pub-id pub-id-type="doi">10.1056/nejmra1904794</pub-id>.<pub-id pub-id-type="pmid">32997910</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="hon70104-cit-0002">
<string-name>
<given-names>J. J.</given-names>
<surname>Trowbridge</surname>
</string-name> and <string-name>
<given-names>D. T.</given-names>
<surname>Starczynowski</surname>
</string-name>, &#x0201c;<article-title>Innate Immune Pathways and Inflammation in Hematopoietic Aging, Clonal Hematopoiesis, and MDS</article-title>,&#x0201d; <source>Journal of Experimental Medicine</source> [Internet], <volume>218</volume>, no. <issue>7</issue> (<year>July 2021</year>), <pub-id pub-id-type="doi">10.1084/jem.20201544</pub-id>.</mixed-citation></ref><ref id="hon70104-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="hon70104-cit-0003">
<string-name>
<given-names>C. T. R.</given-names>
<surname>Vegivinti</surname>
</string-name>, <string-name>
<given-names>P. R.</given-names>
<surname>Keesari</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Veeraballi</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Role of Innate Immunological/Inflammatory Pathways in Myelodysplastic Syndromes and AML: A Narrative Review</article-title>,&#x0201d; <source>Experimental Hematology &#x00026; Oncology</source>
<volume>12</volume>, no. <issue>1</issue> (<year>July 2023</year>): <fpage>60</fpage>, <pub-id pub-id-type="doi">10.1186/s40164-023-00422-1</pub-id>.<pub-id pub-id-type="pmid">37422676</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="hon70104-cit-0004">
<string-name>
<given-names>L.</given-names>
<surname>Nilsson</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Astrand&#x02010;Grundstr&#x000f6;m</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Anderson</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Involvement and Functional Impairment of the CD34(+)CD38(&#x02010;)Thy&#x02010;1(+) Hematopoietic Stem Cell Pool in Myelodysplastic Syndromes With Trisomy 8</article-title>,&#x0201d; <source>Blood</source>
<volume>100</volume>, no. <issue>1</issue> (<year>July 2002</year>): <fpage>259</fpage>&#x02013;<lpage>267</lpage>, <pub-id pub-id-type="doi">10.1182/blood-2001-12-0188</pub-id>.<pub-id pub-id-type="pmid">12070035</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="hon70104-cit-0005">
<string-name>
<given-names>T.</given-names>
<surname>Muto</surname>
</string-name>, <string-name>
<given-names>C. S.</given-names>
<surname>Walker</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Choi</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Adaptive Response to Inflammation Contributes to Sustained Myelopoiesis and Confers a Competitive Advantage in Myelodysplastic Syndrome HSCs</article-title>,&#x0201d; <source>Nature Immunology</source>
<volume>21</volume>, no. <issue>5</issue> (<year>May 2020</year>): <fpage>535</fpage>&#x02013;<lpage>545</lpage>, <pub-id pub-id-type="doi">10.1038/s41590-020-0663-z</pub-id>.<pub-id pub-id-type="pmid">32313245</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0006"><label>6</label><mixed-citation publication-type="miscellaneous" id="hon70104-cit-0006">
<string-name>
<surname>Williams</surname>
<given-names>N.</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Moore</surname>
<given-names>L</given-names>
</string-name>, et&#x000a0;al. &#x0201c;<article-title>Phylogenetic Reconstruction of Myeloproliferative Neoplasm Reveals Very Early Origins and Lifelong Evolution</article-title>,&#x0201d; [Internet] preprint, bioRxiv (<year>2020</year>), <pub-id pub-id-type="doi">10.1101/2020.11.09.374710</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="hon70104-cit-0007">
<string-name>
<given-names>D.</given-names>
<surname>Van Egeren</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Escabi</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Nguyen</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms</article-title>,&#x0201d; <source>Cell Stem Cell</source>
<volume>28</volume>, no. <issue>3</issue> (<year>March 2021</year>): <fpage>514</fpage>&#x02013;<lpage>523.e9</lpage>, <pub-id pub-id-type="doi">10.1016/j.stem.2021.02.001</pub-id>.<pub-id pub-id-type="pmid">33621486</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="hon70104-cit-0008">
<string-name>
<given-names>L.</given-names>
<surname>Barreyro</surname>
</string-name>, <string-name>
<given-names>T. M.</given-names>
<surname>Chlon</surname>
</string-name>, and <string-name>
<given-names>D. T.</given-names>
<surname>Starczynowski</surname>
</string-name>, &#x0201c;<article-title>Chronic Immune Response Dysregulation in MDS Pathogenesis</article-title>,&#x0201d; <source>Blood</source>
<volume>132</volume>, no. <issue>15</issue> (<year>October 2018</year>): <fpage>1553</fpage>&#x02013;<lpage>1560</lpage>, <pub-id pub-id-type="doi">10.1182/blood-2018-03-784116</pub-id>.<pub-id pub-id-type="pmid">30104218</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="hon70104-cit-0009">
<string-name>
<given-names>M. T.</given-names>
<surname>Baldridge</surname>
</string-name>, <string-name>
<given-names>K. Y.</given-names>
<surname>King</surname>
</string-name>, <string-name>
<given-names>N. C.</given-names>
<surname>Boles</surname>
</string-name>, <string-name>
<given-names>D. C.</given-names>
<surname>Weksberg</surname>
</string-name>, and <string-name>
<given-names>M. A.</given-names>
<surname>Goodell</surname>
</string-name>, &#x0201c;<article-title>Quiescent Haematopoietic Stem Cells Are Activated by IFN&#x02010;Gamma in Response to Chronic Infection</article-title>,&#x0201d; <source>Nature</source> [Internet] <volume>465</volume>, no. <issue>7299</issue> (<year>June 2010</year>): <fpage>793</fpage>&#x02013;<lpage>797</lpage>, <pub-id pub-id-type="doi">10.1038/nature09135</pub-id>.<pub-id pub-id-type="pmid">20535209</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="hon70104-cit-0010">
<string-name>
<given-names>V.</given-names>
<surname>Vallelonga</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Gandolfi</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Ficara</surname>
</string-name>, <string-name>
<given-names>M. G.</given-names>
<surname>Della Porta</surname>
</string-name>, and <string-name>
<given-names>S.</given-names>
<surname>Ghisletti</surname>
</string-name>, &#x0201c;<article-title>Emerging Insights into Molecular Mechanisms of Inflammation in Myelodysplastic Syndromes</article-title>,&#x0201d; <source>Biomedicines</source>
<volume>11</volume>, no. <issue>10</issue> (<year>September 2023</year>): <elocation-id>2613</elocation-id>, <pub-id pub-id-type="doi">10.3390/biomedicines11102613</pub-id>.<pub-id pub-id-type="pmid">37892987</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="hon70104-cit-0011">
<string-name>
<given-names>L. C.</given-names>
<surname>Paracatu</surname>
</string-name>, <string-name>
<given-names>D. A.</given-names>
<surname>Monlish</surname>
</string-name>, <string-name>
<given-names>Z. J.</given-names>
<surname>Greenberg</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Toll&#x02010;Like Receptor and Cytokine Expression Throughout the Bone Marrow Differs Between Patients With Low&#x02010; and High&#x02010;Risk Myelodysplastic Syndromes</article-title>,&#x0201d; <source>Experimental Hematology</source>
<volume>110</volume> (<year>June 2022</year>): <fpage>47</fpage>&#x02013;<lpage>59</lpage>, <pub-id pub-id-type="doi">10.1016/j.exphem.2022.03.011</pub-id>.<pub-id pub-id-type="pmid">35367529</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="hon70104-cit-0012">
<string-name>
<given-names>A. G.</given-names>
<surname>de Matos</surname>
</string-name>, <string-name>
<given-names>H. L.</given-names>
<surname>Ribeiro Junior</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>de Paula Borges</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Interleukin&#x02010;8 and Nuclear Factor Kappa B Are Increased and Positively Correlated in Myelodysplastic Syndrome</article-title>,&#x0201d; <source>Medical Oncology</source>
<volume>34</volume>, no. <issue>10</issue> (<year>August 2017</year>): <fpage>168</fpage>, <pub-id pub-id-type="doi">10.1007/s12032-017-1023-1</pub-id>.<pub-id pub-id-type="pmid">28856536</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="hon70104-cit-0013">
<string-name>
<given-names>V. R.</given-names>
<surname>Gummadi</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Boruah</surname>
</string-name>, <string-name>
<given-names>B. R.</given-names>
<surname>Ainan</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Discovery of CA&#x02010;4948, an Orally Bioavailable IRAK4 Inhibitor for Treatment of Hematologic Malignancies</article-title>,&#x0201d; <source>ACS Medicinal Chemistry Letters</source>
<volume>11</volume>, no. <issue>12</issue> (<year>December 2020</year>): <fpage>2374</fpage>&#x02013;<lpage>2381</lpage>, <pub-id pub-id-type="doi">10.1021/acsmedchemlett.0c00255</pub-id>.<pub-id pub-id-type="pmid">33335659</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="hon70104-cit-0014">
<string-name>
<given-names>S.</given-names>
<surname>Dimicoli</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Wei</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Bueso&#x02010;Ramos</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Overexpression of the Toll&#x02010;Like Receptor (TLR) Signaling Adaptor MYD88, But Lack of Genetic Mutation, in Myelodysplastic Syndromes</article-title>,&#x0201d; <source>PLoS One</source>
<volume>8</volume>, no. <issue>8</issue> (<year>August 2013</year>): <elocation-id>e71120</elocation-id>, <pub-id pub-id-type="doi">10.1371/journal.pone.0071120</pub-id>.<pub-id pub-id-type="pmid">23976989</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="hon70104-cit-0015">
<string-name>
<given-names>X.</given-names>
<surname>Peng</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Zhu</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Di</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>The Yin&#x02010;Yang of Immunity: Immune Dysregulation in Myelodysplastic Syndrome With Different Risk Stratification</article-title>,&#x0201d; <source>Frontiers in Immunology</source>
<volume>13</volume> (<year>September 2022</year>): <elocation-id>994053</elocation-id>, <pub-id pub-id-type="doi">10.3389/fimmu.2022.994053</pub-id>.<pub-id pub-id-type="pmid">36211357</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="hon70104-cit-0016">
<string-name>
<given-names>M.</given-names>
<surname>Kanehisa</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Furumichi</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Sato</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Kawashima</surname>
</string-name>, and <string-name>
<given-names>M.</given-names>
<surname>Ishiguro&#x02010;Watanabe</surname>
</string-name>, &#x0201c;<article-title>KEGG for Taxonomy&#x02010;Based Analysis of Pathways and Genomes</article-title>,&#x0201d; <source>Nucleic Acids Research</source>
<volume>51</volume>, no. <issue>D1</issue> (<year>January 2023</year>): <fpage>D587</fpage>&#x02013;<lpage>D592</lpage>, <pub-id pub-id-type="doi">10.1093/nar/gkac963</pub-id>.<pub-id pub-id-type="pmid">36300620</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="hon70104-cit-0017">
<string-name>
<given-names>M.</given-names>
<surname>Kanehisa</surname>
</string-name> and <string-name>
<given-names>S.</given-names>
<surname>Goto</surname>
</string-name>, &#x0201c;<article-title>KEGG: Kyoto Encyclopedia of Genes and Genomes</article-title>,&#x0201d; <source>Nucleic Acids Research</source>
<volume>28</volume>, no. <issue>1</issue> (<year>January 2000</year>): <fpage>27</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">10592173</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="hon70104-cit-0018">
<string-name>
<given-names>A. M.</given-names>
<surname>Newman</surname>
</string-name>, <string-name>
<given-names>C. L.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>M. R.</given-names>
<surname>Green</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Robust Enumeration of Cell Subsets From Tissue Expression Profiles</article-title>,&#x0201d; <source>Nature Methods</source>
<volume>12</volume>, no. <issue>5</issue> (<year>May 2015</year>): <fpage>453</fpage>&#x02013;<lpage>457</lpage>, <pub-id pub-id-type="doi">10.1038/nmeth.3337</pub-id>.<pub-id pub-id-type="pmid">25822800</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0019"><label>19</label><mixed-citation publication-type="book" id="hon70104-cit-0019">
<string-name>
<given-names>H. C.</given-names>
<surname>Wang</surname>
</string-name> and <string-name>
<given-names>S.</given-names>
<surname>Fedoroff</surname>
</string-name>, &#x0201c;<part-title>Karyology of Cells in Culture</part-title>,&#x0201d; in <source>Tissue Culture</source> (<publisher-name>Elsevier</publisher-name>, <year>1973</year>), <fpage>782</fpage>&#x02013;<lpage>787</lpage>.</mixed-citation></ref><ref id="hon70104-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="hon70104-cit-0020">
<string-name>
<given-names>J. D.</given-names>
<surname>Khoury</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Solary</surname>
</string-name>, <string-name>
<given-names>O.</given-names>
<surname>Abla</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms</article-title>,&#x0201d; <source>Leukemia</source>
<volume>36</volume>, no. <issue>7</issue> (<year>July 2022</year>): <fpage>1703</fpage>&#x02013;<lpage>1719</lpage>, <pub-id pub-id-type="doi">10.1038/s41375-022-01613-1</pub-id>.<pub-id pub-id-type="pmid">35732831</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="hon70104-cit-0021">
<string-name>
<given-names>M.</given-names>
<surname>Schneider</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Rolfs</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Trumpp</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Activation of Distinct Inflammatory Pathways in Subgroups of LR&#x02010;MDS</article-title>,&#x0201d; <source>Leukemia</source>
<volume>37</volume>, no. <issue>8</issue> (<year>August 2023</year>): <fpage>1709</fpage>&#x02013;<lpage>1718</lpage>, <pub-id pub-id-type="doi">10.1038/s41375-023-01949-2</pub-id>.<pub-id pub-id-type="pmid">37420006</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="hon70104-cit-0022">
<string-name>
<given-names>L.</given-names>
<surname>Chee</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Ritchie</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Ludford&#x02010;Menting</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Dysregulation of Immune Cell and Cytokine Signalling Correlates With Clinical Outcomes in Myelodysplastic Syndrome (MDS)</article-title>,&#x0201d; <source>European Journal of Haematology</source>
<volume>108</volume>, no. <issue>4</issue> (<year>April 2022</year>): <fpage>342</fpage>&#x02013;<lpage>353</lpage>.<pub-id pub-id-type="pmid">34963023</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="hon70104-cit-0023">
<string-name>
<given-names>A.</given-names>
<surname>Glenth&#x000f8;j</surname>
</string-name>, <string-name>
<given-names>A. D.</given-names>
<surname>&#x000d8;rskov</surname>
</string-name>, <string-name>
<given-names>J. W.</given-names>
<surname>Hansen</surname>
</string-name>, <string-name>
<given-names>S. R.</given-names>
<surname>Hadrup</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>O&#x02019;Connell</surname>
</string-name>, and <string-name>
<given-names>K.</given-names>
<surname>Gr&#x000f8;nb&#x000e6;k</surname>
</string-name>, &#x0201c;<article-title>Immune Mechanisms in Myelodysplastic Syndrome</article-title>,&#x0201d; <source>International Journal of Molecular Sciences</source>
<volume>17</volume>, no. <issue>6</issue> (<year>June 2016</year>): <elocation-id>944</elocation-id>, <pub-id pub-id-type="doi">10.3390/ijms17060944</pub-id>.<pub-id pub-id-type="pmid">27314337</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="hon70104-cit-0024">
<string-name>
<given-names>I.</given-names>
<surname>Ga&#x000f1;&#x000e1;n&#x02010;G&#x000f3;mez</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Wei</surname>
</string-name>, <string-name>
<given-names>D. T.</given-names>
<surname>Starczynowski</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Deregulation of Innate Immune and Inflammatory Signaling in Myelodysplastic Syndromes</article-title>,&#x0201d; <source>Leukemia</source>
<volume>29</volume>, no. <issue>7</issue> (<year>July 2015</year>): <fpage>1458</fpage>&#x02013;<lpage>1469</lpage>, <pub-id pub-id-type="doi">10.1038/leu.2015.69</pub-id>.<pub-id pub-id-type="pmid">25761935</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="hon70104-cit-0025">
<string-name>
<given-names>Y.</given-names>
<surname>Wei</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Dimicoli</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Bueso&#x02010;Ramos</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Toll&#x02010;Like Receptor Alterations in Myelodysplastic Syndrome</article-title>,&#x0201d; <source>Leukemia</source>
<volume>27</volume>, no. <issue>9</issue> (<year>September 2013</year>): <fpage>1832</fpage>&#x02013;<lpage>1840</lpage>, <pub-id pub-id-type="doi">10.1038/leu.2013.180</pub-id>.<pub-id pub-id-type="pmid">23765228</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="hon70104-cit-0026">
<string-name>
<given-names>L.</given-names>
<surname>Su&#x000e1;rez</surname>
</string-name>, <string-name>
<given-names>M. B.</given-names>
<surname>Vidriales</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Garc&#x000ed;a&#x02010;Lara&#x000f1;a</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>CD34+ Cells From Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Normal Bone Marrow Display Different Apoptosis and Drug Resistance&#x02010;Associated Phenotypes</article-title>,&#x0201d; <source>Clinical Cancer Research</source>
<volume>10</volume>, no. <issue>22</issue> (<year>November 2004</year>): <fpage>7599</fpage>&#x02013;<lpage>7606</lpage>, <pub-id pub-id-type="doi">10.1158/1078-0432.ccr-04-0598</pub-id>.<pub-id pub-id-type="pmid">15569991</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="hon70104-cit-0027">
<string-name>
<given-names>T.</given-names>
<surname>Xing</surname>
</string-name>, <string-name>
<given-names>W. L.</given-names>
<surname>Yao</surname>
</string-name>, <string-name>
<given-names>H. Y.</given-names>
<surname>Zhao</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Bone Marrow Macrophages Are Involved in the Ineffective Hematopoiesis of Myelodysplastic Syndromes</article-title>,&#x0201d; <source>Journal of Cellular Physiology</source>
<volume>239</volume>, no. <issue>2</issue> (<year>February 2024</year>): <elocation-id>e31129</elocation-id>, <pub-id pub-id-type="doi">10.1002/jcp.31129</pub-id>.<pub-id pub-id-type="pmid">38192063</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="hon70104-cit-0028">
<string-name>
<given-names>S. J.</given-names>
<surname>Xu</surname>
</string-name>, <string-name>
<given-names>Z. H.</given-names>
<surname>Shao</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Fu</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Subtype and Functional Biomarker Changes of NK Cells in Peripheral Blood of Patients With Myelodysplastic Syndrome</article-title>,&#x0201d; <source>Zhongguo Shi Yan Xue Ye Xue Za Zhi</source>
<volume>25</volume>, no. <issue>3</issue> (<year>June 2017</year>): <fpage>832</fpage>&#x02013;<lpage>836</lpage>.<pub-id pub-id-type="pmid">28641645</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="hon70104-cit-0029">
<string-name>
<given-names>M.</given-names>
<surname>Carlsten</surname>
</string-name> and <string-name>
<given-names>M.</given-names>
<surname>J&#x000e4;r&#x000e5;s</surname>
</string-name>, &#x0201c;<article-title>Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells</article-title>,&#x0201d; <source>Frontiers in Immunology</source>
<volume>10</volume> (<year>October 2019</year>): <elocation-id>2357</elocation-id>, <pub-id pub-id-type="doi">10.3389/fimmu.2019.02357</pub-id>.<pub-id pub-id-type="pmid">31681270</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="hon70104-cit-0030">
<string-name>
<given-names>T.</given-names>
<surname>Braun</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Carvalho</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Coquelle</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>NF&#x02010;kappaB Constitutes a Potential Therapeutic Target in High&#x02010;Risk Myelodysplastic Syndrome</article-title>,&#x0201d; <source>Blood</source>
<volume>107</volume>, no. <issue>3</issue> (<year>February 2006</year>): <fpage>1156</fpage>&#x02013;<lpage>1165</lpage>, <pub-id pub-id-type="doi">10.1182/blood-2005-05-1989</pub-id>.<pub-id pub-id-type="pmid">16223780</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="hon70104-cit-0031">
<string-name>
<given-names>J.</given-names>
<surname>Fang</surname>
</string-name>, <string-name>
<given-names>L. C.</given-names>
<surname>Bolanos</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Choi</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Ubiquitination of hnRNPA1 by TRAF6 Links Chronic Innate Immune Signaling With Myelodysplasia</article-title>,&#x0201d; <source>Nature Immunology</source>
<volume>18</volume>, no. <issue>2</issue> (<year>February 2017</year>): <fpage>236</fpage>&#x02013;<lpage>245</lpage>, <pub-id pub-id-type="doi">10.1038/ni.3654</pub-id>.<pub-id pub-id-type="pmid">28024152</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="hon70104-cit-0032">
<string-name>
<given-names>G. W.</given-names>
<surname>Rhyasen</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Bolanos</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Fang</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Targeting IRAK1 as a Therapeutic Approach for Myelodysplastic Syndrome</article-title>,&#x0201d; <source>Cancer Cell</source>
<volume>24</volume>, no. <issue>1</issue> (<year>July 2013</year>): <fpage>90</fpage>&#x02013;<lpage>104</lpage>, <pub-id pub-id-type="doi">10.1016/j.ccr.2013.05.006</pub-id>.<pub-id pub-id-type="pmid">23845443</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="hon70104-cit-0033">
<string-name>
<given-names>M.</given-names>
<surname>Daher</surname>
</string-name>, <string-name>
<given-names>J. E.</given-names>
<surname>Hidalgo Lopez</surname>
</string-name>, <string-name>
<given-names>J. K.</given-names>
<surname>Randhawa</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>An Exploratory Clinical Trial of Bortezomib in Patients With Lower Risk Myelodysplastic Syndromes</article-title>,&#x0201d; <source>American Journal of Hematology</source>
<volume>92</volume>, no. <issue>7</issue> (<year>July 2017</year>): <fpage>674</fpage>&#x02013;<lpage>682</lpage>, <pub-id pub-id-type="doi">10.1002/ajh.24746</pub-id>.<pub-id pub-id-type="pmid">28370157</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="hon70104-cit-0034">
<string-name>
<given-names>H.</given-names>
<surname>Chen</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>R. A.</given-names>
<surname>Campbell</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Interference With Nuclear Factor Kappa B and C&#x02010;Jun NH2&#x02010;terminal Kinase Signaling by TRAF6C Small Interfering RNA Inhibits Myeloma Cell Proliferation and Enhances Apoptosis</article-title>,&#x0201d; <source>Oncogene</source>
<volume>25</volume>, no. <issue>49</issue> (<year>October 2006</year>): <fpage>6520</fpage>&#x02013;<lpage>6527</lpage>, <pub-id pub-id-type="doi">10.1038/sj.onc.1209653</pub-id>.<pub-id pub-id-type="pmid">16702955</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="hon70104-cit-0035">
<string-name>
<given-names>G.</given-names>
<surname>Garcia&#x02010;Manero</surname>
</string-name>, <string-name>
<given-names>E. S.</given-names>
<surname>Winer</surname>
</string-name>, <string-name>
<given-names>D. J.</given-names>
<surname>DeAngelo</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>S129: Takeaim Leukemia&#x02010; A Phase 1/2a Study of the Irak4 Inhibitor Emavusertib (Ca&#x02010;4948) as Monotherapy or in Combination With Azacitidine or Venetoclax in Relapsed/refractory Aml or Mds</article-title>,&#x0201d; <source>HemaSphere</source>
<volume>6</volume> (<year>June 2022</year>): <fpage>30</fpage>&#x02013;<lpage>31</lpage>, <pub-id pub-id-type="doi">10.1097/01.hs9.0000843408.31385.3f</pub-id>.</mixed-citation></ref><ref id="hon70104-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="hon70104-cit-0036">
<string-name>
<given-names>M. E.</given-names>
<surname>Varney</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Melgar</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Niederkorn</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Smith</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Barreyro</surname>
</string-name>, and <string-name>
<given-names>D. T.</given-names>
<surname>Starczynowski</surname>
</string-name>, &#x0201c;<article-title>Deconstructing Innate Immune Signaling in Myelodysplastic Syndromes</article-title>,&#x0201d; <source>Experimental Hematology</source>
<volume>43</volume>, no. <issue>8</issue> (<year>August 2015</year>): <fpage>587</fpage>&#x02013;<lpage>598</lpage>, <pub-id pub-id-type="doi">10.1016/j.exphem.2015.05.016</pub-id>.<pub-id pub-id-type="pmid">26143580</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="hon70104-cit-0037">
<string-name>
<given-names>L. C.</given-names>
<surname>Paracatu</surname>
</string-name> and <string-name>
<given-names>L. G.</given-names>
<surname>Schuettpelz</surname>
</string-name>, &#x0201c;<article-title>Contribution of Aberrant Toll Like Receptor Signaling to the Pathogenesis of Myelodysplastic Syndromes</article-title>,&#x0201d; <source>Frontiers in Immunology</source>
<volume>11</volume> (<year>June 2020</year>): <elocation-id>1236</elocation-id>, <pub-id pub-id-type="doi">10.3389/fimmu.2020.01236</pub-id>.<pub-id pub-id-type="pmid">32625214</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="hon70104-cit-0038">
<string-name>
<given-names>L.</given-names>
<surname>Chen</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Zheng</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Chen</surname>
</string-name>, and <string-name>
<given-names>G.</given-names>
<surname>Liang</surname>
</string-name>, &#x0201c;<article-title>Myeloid Differentiation Primary Response Protein 88 (MyD88): The Central Hub of TLR/IL&#x02010;1R Signaling</article-title>,&#x0201d; <source>Journal of Medicinal Chemistry</source>
<volume>63</volume>, no. <issue>22</issue> (<year>November 2020</year>): <fpage>13316</fpage>&#x02013;<lpage>13329</lpage>, <pub-id pub-id-type="doi">10.1021/acs.jmedchem.0c00884</pub-id>.<pub-id pub-id-type="pmid">32931267</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="hon70104-cit-0039">
<string-name>
<given-names>C.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Zienkiewicz</surname>
</string-name>, and <string-name>
<given-names>J.</given-names>
<surname>Hawiger</surname>
</string-name>, &#x0201c;<article-title>Interactive Sites in the MyD88 Toll/Interleukin (IL) 1 Receptor Domain Responsible for Coupling to the IL1beta Signaling Pathway</article-title>,&#x0201d; <source>Journal of Biological Chemistry</source>
<volume>280</volume>, no. <issue>28</issue> (<year>July 2005</year>): <fpage>26152</fpage>&#x02013;<lpage>26159</lpage>, <pub-id pub-id-type="doi">10.1074/jbc.m503262200</pub-id>.<pub-id pub-id-type="pmid">15849357</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="hon70104-cit-0040">
<string-name>
<given-names>J.</given-names>
<surname>Vaquero</surname>
</string-name>, <string-name>
<given-names>J. S.</given-names>
<surname>Campbell</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Haque</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Toll&#x02010;Like Receptor 4 and Myeloid Differentiation Factor 88 Provide Mechanistic Insights Into the Cause and Effects of Interleukin&#x02010;6 Activation in Mouse Liver Regeneration</article-title>,&#x0201d; <source>Hepatology</source>
<volume>54</volume>, no. <issue>2</issue> (<year>August 2011</year>): <fpage>597</fpage>&#x02013;<lpage>608</lpage>, <pub-id pub-id-type="doi">10.1002/hep.24420</pub-id>.<pub-id pub-id-type="pmid">21574169</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="hon70104-cit-0041">
<string-name>
<given-names>M.</given-names>
<surname>Jongen&#x02010;Lavrencic</surname>
</string-name>, <string-name>
<given-names>H. R.</given-names>
<surname>Peeters</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Rozemuller</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>IL&#x02010;6&#x02010;Induced Anaemia in Rats: Possible Pathogenetic Implications for Anemia Observed in Chronic Inflammations</article-title>,&#x0201d; <source>Clinical and Experimental Immunology</source>
<volume>103</volume>, no. <issue>2</issue> (<year>February 1996</year>): <fpage>328</fpage>&#x02013;<lpage>334</lpage>, <pub-id pub-id-type="doi">10.1046/j.1365-2249.1996.d01-622.x</pub-id>.<pub-id pub-id-type="pmid">8565320</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="hon70104-cit-0042">
<string-name>
<given-names>J.</given-names>
<surname>Krajewski</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Batmunkh</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Jelkmann</surname>
</string-name>, and <string-name>
<given-names>T.</given-names>
<surname>Hellwig&#x02010;B&#x000fc;rgel</surname>
</string-name>, &#x0201c;<article-title>Interleukin&#x02010;1&#x003b2; Inhibits the Hypoxic Inducibility of the Erythropoietin Enhancer by Suppressing Hepatocyte Nuclear Factor&#x02010;4&#x003b1;</article-title>,&#x0201d; <source>Cellular and Molecular Life Sciences</source>
<volume>64</volume>, no. <issue>7&#x02013;8</issue> (<year>April 2007</year>): <fpage>989</fpage>&#x02013;<lpage>998</lpage>, <pub-id pub-id-type="doi">10.1007/s00018-007-6561-9</pub-id>.<pub-id pub-id-type="pmid">17372675</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="hon70104-cit-0043">
<string-name>
<given-names>R. T. Jr</given-names>
<surname>Means</surname>
</string-name>, <string-name>
<given-names>E. N.</given-names>
<surname>Dessypris</surname>
</string-name>, and <string-name>
<given-names>S. B.</given-names>
<surname>Krantz</surname>
</string-name>, &#x0201c;<article-title>Inhibition of Human Erythroid Colony&#x02010;Forming Units by Interleukin&#x02010;1 is Mediated by Gamma Interferon</article-title>,&#x0201d; <source>Journal of Cellular Physiology</source>
<volume>150</volume>, no. <issue>1</issue> (<year>January 1992</year>): <fpage>59</fpage>&#x02013;<lpage>64</lpage>, <pub-id pub-id-type="doi">10.1002/jcp.1041500109</pub-id>.<pub-id pub-id-type="pmid">1730787</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="hon70104-cit-0044">
<string-name>
<given-names>N.</given-names>
<surname>Ramachandra</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Gupta</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Schwartz</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Role of IL8 in Myeloid Malignancies</article-title>,&#x0201d; <source>Leukemia and Lymphoma</source>
<volume>64</volume>, no. <issue>11</issue> (<year>November 2023</year>): <fpage>1742</fpage>&#x02013;<lpage>1751</lpage>, <pub-id pub-id-type="doi">10.1080/10428194.2023.2232492</pub-id>.<pub-id pub-id-type="pmid">37467070</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="hon70104-cit-0045">
<string-name>
<given-names>K. A.</given-names>
<surname>Lord</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Hoffman&#x02010;Liebermann</surname>
</string-name>, and <string-name>
<given-names>D. A.</given-names>
<surname>Liebermann</surname>
</string-name>, &#x0201c;<article-title>Nucleotide Sequence and Expression of a cDNA Encoding MyD88, a Novel Myeloid Differentiation Primary Response Gene Induced by IL6</article-title>,&#x0201d; <source>Oncogene</source>
<volume>5</volume>, no. <issue>7</issue> (<year>July 1990</year>): <fpage>1095</fpage>&#x02013;<lpage>1097</lpage>.<pub-id pub-id-type="pmid">2374694</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="hon70104-cit-0046">
<string-name>
<given-names>Y.</given-names>
<surname>Zhang</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Jones</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>McCabe</surname>
</string-name>, <string-name>
<given-names>G. M.</given-names>
<surname>Winslow</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Avram</surname>
</string-name>, and <string-name>
<given-names>K. C.</given-names>
<surname>MacNamara</surname>
</string-name>, &#x0201c;<article-title>MyD88 Signaling in CD4 T Cells Promotes IFN&#x02010;&#x003b3; Production and Hematopoietic Progenitor Cell Expansion in Response to Intracellular Bacterial Infection</article-title>,&#x0201d; <source>Journal of Immunology</source>
<volume>190</volume>, no. <issue>9</issue> (<year>May 2013</year>): <fpage>4725</fpage>&#x02013;<lpage>4735</lpage>, <pub-id pub-id-type="doi">10.4049/jimmunol.1203024</pub-id>.</mixed-citation></ref><ref id="hon70104-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="hon70104-cit-0047">
<string-name>
<given-names>K.</given-names>
<surname>Fiedler</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Kokai</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Bresch</surname>
</string-name>, and <string-name>
<given-names>C.</given-names>
<surname>Brunner</surname>
</string-name>, &#x0201c;<article-title>MyD88 is Involved in Myeloid as Well as Lymphoid Hematopoiesis Independent of the Presence of a Pathogen</article-title>,&#x0201d; <source>American Journal of Blood Research</source>
<volume>3</volume>, no. <issue>2</issue> (<year>May 2013</year>): <fpage>124</fpage>&#x02013;<lpage>140</lpage>.<pub-id pub-id-type="pmid">23675564</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="hon70104-cit-0048">
<string-name>
<given-names>M.</given-names>
<surname>Samba&#x02010;Mondonga</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Calv&#x000e9;</surname>
</string-name>, <string-name>
<given-names>F. A.</given-names>
<surname>Mallette</surname>
</string-name>, and <string-name>
<given-names>M. M.</given-names>
<surname>Santos</surname>
</string-name>, &#x0201c;<article-title>MyD88 Regulates the Expression of SMAD4 and the Iron Regulatory Hormone Hepcidin</article-title>,&#x0201d; <source>Frontiers in Cell and Developmental Biology</source>
<volume>6</volume> (<year>August 2018</year>): <elocation-id>105</elocation-id>, <pub-id pub-id-type="doi">10.3389/fcell.2018.00105</pub-id>.<pub-id pub-id-type="pmid">30234111</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="hon70104-cit-0049">
<string-name>
<given-names>A.</given-names>
<surname>Layoun</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Samba&#x02010;Mondonga</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Fragoso</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Calv&#x000e9;</surname>
</string-name>, and <string-name>
<given-names>M. M.</given-names>
<surname>Santos</surname>
</string-name>, &#x0201c;<article-title>MyD88 Adaptor Protein is Required for Appropriate Hepcidin Induction in Response to Dietary Iron Overload in Mice</article-title>,&#x0201d; <source>Frontiers in Physiology</source>
<volume>9</volume> (<year>March 2018</year>): <elocation-id>159</elocation-id>, <pub-id pub-id-type="doi">10.3389/fphys.2018.00159</pub-id>.<pub-id pub-id-type="pmid">29556203</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="hon70104-cit-0050">
<string-name>
<given-names>O.</given-names>
<surname>Adachi</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Kawai</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Takeda</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Targeted Disruption of the MyD88 Gene Results in Loss of IL&#x02010;1&#x02010; and IL&#x02010;18&#x02010;Mediated Function</article-title>,&#x0201d; <source>Immunity</source>
<volume>9</volume>, no. <issue>1</issue> (<year>July 1998</year>): <fpage>143</fpage>&#x02013;<lpage>150</lpage>, <pub-id pub-id-type="doi">10.1016/s1074-7613(00)80596-8</pub-id>.<pub-id pub-id-type="pmid">9697844</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="hon70104-cit-0051">
<string-name>
<given-names>M. E.</given-names>
<surname>Varney</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Niederkorn</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Konno</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Loss of Tifab, a del(5q) MDS Gene, Alters Hematopoiesis Through Derepression Of Toll&#x02010;Like Receptor&#x02010;TRAF6 Signaling</article-title>,&#x0201d; <source>Journal of Experimental Medicine</source>
<volume>212</volume>, no. <issue>11</issue> (<year>October 2015</year>): <fpage>1967</fpage>&#x02013;<lpage>1985</lpage>, <pub-id pub-id-type="doi">10.1084/jem.20141898</pub-id>.<pub-id pub-id-type="pmid">26458771</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="hon70104-cit-0052">
<string-name>
<given-names>Y. H.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>H. A.</given-names>
<surname>Hou</surname>
</string-name>, <string-name>
<given-names>C. C.</given-names>
<surname>Lin</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>A CIBERSORTx&#x02010;Based Immune Cell Scoring System Could Independently Predict the Prognosis of Patients With Myelodysplastic Syndromes</article-title>,&#x0201d; <source>Blood Advances</source>
<volume>5</volume>, no. <issue>22</issue> (<year>November 2021</year>): <fpage>4535</fpage>&#x02013;<lpage>4548</lpage>, <pub-id pub-id-type="doi">10.1182/bloodadvances.2021005141</pub-id>.<pub-id pub-id-type="pmid">34614508</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="hon70104-cit-0053">
<string-name>
<given-names>J.</given-names>
<surname>Bennett</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Ishikawa</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Agarwal</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Paralog&#x02010;specific Signaling by IRAK1/4 Maintains MyD88&#x02010;Independent Functions in MDS/AML</article-title>,&#x0201d; <source>Blood</source>
<volume>142</volume>, no. <issue>11</issue> (<year>September 2023</year>): <fpage>989</fpage>&#x02013;<lpage>1007</lpage>, <pub-id pub-id-type="doi">10.1182/blood.2022018718</pub-id>.<pub-id pub-id-type="pmid">37172199</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="hon70104-cit-0054">
<string-name>
<given-names>R. D.</given-names>
<surname>Parrondo</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Iqbal</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Von Roemeling</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Von Roemeling</surname>
</string-name>, and <string-name>
<given-names>H. W.</given-names>
<surname>Tun</surname>
</string-name>, &#x0201c;<article-title>IRAK&#x02010;4 Inhibition: Emavusertib for the Treatment of Lymphoid and Myeloid Malignancies</article-title>,&#x0201d; <source>Frontiers in Immunology</source>
<volume>14</volume> (<year>October 2023</year>): <elocation-id>1239082</elocation-id>, <pub-id pub-id-type="doi">10.3389/fimmu.2023.1239082</pub-id>.<pub-id pub-id-type="pmid">37954584</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="hon70104-cit-0055">
<string-name>
<given-names>A.</given-names>
<surname>Wojtuszkiewicz</surname>
</string-name>, <string-name>
<given-names>G. J.</given-names>
<surname>Schuurhuis</surname>
</string-name>, <string-name>
<given-names>F. L.</given-names>
<surname>Kessler</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Exosomes Secreted by Apoptosis&#x02010;Resistant Acute Myeloid Leukemia (AML) Blasts Harbor Regulatory Network Proteins Potentially Involved in Antagonism of Apoptosis</article-title>,&#x0201d; <source>Molecular &#x00026; Cellular Proteomics</source>
<volume>15</volume>, no. <issue>4</issue> (<year>April 2016</year>): <fpage>1281</fpage>&#x02013;<lpage>1298</lpage>, <pub-id pub-id-type="doi">10.1074/mcp.m115.052944</pub-id>.<pub-id pub-id-type="pmid">26801919</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="hon70104-cit-0056">
<string-name>
<given-names>A. M.</given-names>
<surname>Abdul&#x02010;Aziz</surname>
</string-name>, <string-name>
<given-names>M. S.</given-names>
<surname>Shafat</surname>
</string-name>, <string-name>
<given-names>T. K.</given-names>
<surname>Mehta</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>MIF&#x02010;Induced Stromal PKC&#x003b2;/IL8 is Essential in Human Acute Myeloid Leukemia</article-title>,&#x0201d; <source>Cancer Research</source>
<volume>77</volume>, no. <issue>2</issue> (<year>January 2017</year>): <fpage>303</fpage>&#x02013;<lpage>311</lpage>, <pub-id pub-id-type="doi">10.1158/0008-5472.can-16-1095</pub-id>.<pub-id pub-id-type="pmid">27872094</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="hon70104-cit-0057">
<string-name>
<given-names>J.</given-names>
<surname>Schanz</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Steidl</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Fonatsch</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Coalesced Multicentric Analysis of 2,351 Patients With Myelodysplastic Syndromes Indicates an Underestimation of Poor&#x02010;Risk Cytogenetics of Myelodysplastic Syndromes in the International Prognostic Scoring System</article-title>,&#x0201d; <source>Journal of Clinical Oncology</source>
<volume>29</volume>, no. <issue>15</issue> (<year>May 2011</year>): <fpage>1963</fpage>&#x02013;<lpage>1970</lpage>, <pub-id pub-id-type="doi">10.1200/jco.2010.28.3978</pub-id>.<pub-id pub-id-type="pmid">21519021</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0058"><label>58</label><mixed-citation publication-type="journal" id="hon70104-cit-0058">
<string-name>
<given-names>J.</given-names>
<surname>Neukirchen</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Lauseker</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Hildebrandt</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Cytogenetic Clonal Evolution in Myelodysplastic Syndromes is Associated With Inferior Prognosis</article-title>,&#x0201d; <source>Cancer</source>
<volume>123</volume>, no. <issue>23</issue> (<year>December 2017</year>): <fpage>4608</fpage>&#x02013;<lpage>4616</lpage>, <pub-id pub-id-type="doi">10.1002/cncr.30917</pub-id>.<pub-id pub-id-type="pmid">28746789</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0059"><label>59</label><mixed-citation publication-type="journal" id="hon70104-cit-0059">
<string-name>
<given-names>I.</given-names>
<surname>Sayers</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Thakker</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Billington</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Interleukin&#x02010;1 Receptor&#x02010;Associated Kinase 4 (IRAK4) is a Critical Regulator of Inflammatory Signalling Through Toll&#x02010;Like Receptors 4 and 7/8 in Murine and Human Lungs</article-title>,&#x0201d; <source>British Journal of Pharmacology</source>
<volume>181</volume>, no. <issue>22</issue> (<year>November 2024</year>): <fpage>4647</fpage>&#x02013;<lpage>4657</lpage>, <pub-id pub-id-type="doi">10.1111/bph.16509</pub-id>.<pub-id pub-id-type="pmid">39137914</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0060"><label>60</label><mixed-citation publication-type="journal" id="hon70104-cit-0060">
<string-name>
<given-names>X.</given-names>
<surname>Li</surname>
</string-name>, &#x0201c;<article-title>IRAK4 in TLR/IL&#x02010;1R Signaling: Possible Clinical Applications</article-title>,&#x0201d; <source>European Journal of Immunology</source>
<volume>38</volume>, no. <issue>3</issue> (<year>March 2008</year>): <fpage>614</fpage>&#x02013;<lpage>618</lpage>, <pub-id pub-id-type="doi">10.1002/eji.200838161</pub-id>.<pub-id pub-id-type="pmid">18286571</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0061"><label>61</label><mixed-citation publication-type="journal" id="hon70104-cit-0061">
<string-name>
<given-names>S.</given-names>
<surname>De</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Karim</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Kiessu</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Mechanism of Dysfunction of Human Variants of the IRAK4 Kinase and a Role for Its Kinase Activity in Interleukin&#x02010;1 Receptor Signaling</article-title>,&#x0201d; <source>Journal of Biological Chemistry</source>
<volume>293</volume>, no. <issue>39</issue> (<year>September 2018</year>): <fpage>15208</fpage>&#x02013;<lpage>15220</lpage>, <pub-id pub-id-type="doi">10.1074/jbc.ra118.003831</pub-id>.<pub-id pub-id-type="pmid">30115681</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0062"><label>62</label><mixed-citation publication-type="journal" id="hon70104-cit-0062">
<string-name>
<given-names>M.</given-names>
<surname>Koziczak&#x02010;Holbro</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Joyce</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Gl&#x000fc;ck</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>IRAK&#x02010;4 Kinase Activity is Required for Interleukin&#x02010;1 (IL&#x02010;1) Receptor&#x02010; and Toll&#x02010;Like Receptor 7&#x02010;Mediated Signaling and Gene Expression</article-title>,&#x0201d; <source>Journal of Biological Chemistry</source>
<volume>282</volume>, no. <issue>18</issue> (<year>May 2007</year>): <fpage>13552</fpage>&#x02013;<lpage>13560</lpage>.<pub-id pub-id-type="pmid">17337443</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0063"><label>63</label><mixed-citation publication-type="journal" id="hon70104-cit-0063">
<string-name>
<given-names>H. L.</given-names>
<surname>Ribeiro Junior</surname>
</string-name>, <string-name>
<given-names>P. G.</given-names>
<surname>Gon&#x000e7;alves</surname>
</string-name>, <string-name>
<given-names>D. A.</given-names>
<surname>Moreno</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Discrepancy in Transcriptomic Profiling Between CD34 + Stem Cells and Primary Bone Marrow Cells in Myelodysplastic Neoplasm</article-title>,&#x0201d; <source>Leukemia Research</source>
<volume>129</volume>, no. <issue>107071</issue> (<year>June 2023</year>): <elocation-id>107071</elocation-id>.<pub-id pub-id-type="pmid">37004280</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0064"><label>64</label><mixed-citation publication-type="journal" id="hon70104-cit-0064">
<string-name>
<given-names>Y. H.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>C. C.</given-names>
<surname>Lin</surname>
</string-name>, <string-name>
<given-names>C. Y.</given-names>
<surname>Yao</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Immune Signatures of Bone Marrow Cells Can Independently Predict Prognosis in Patients With Myelodysplastic Syndrome</article-title>,&#x0201d; <source>British Journal of Haematology</source>
<volume>196</volume>, no. <issue>1</issue> (<year>January 2022</year>): <fpage>156</fpage>&#x02013;<lpage>168</lpage>, <pub-id pub-id-type="doi">10.1111/bjh.17837</pub-id>.<pub-id pub-id-type="pmid">34536013</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0065"><label>65</label><mixed-citation publication-type="journal" id="hon70104-cit-0065">
<string-name>
<given-names>D.</given-names>
<surname>Aran</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Hu</surname>
</string-name>, and <string-name>
<given-names>A. J.</given-names>
<surname>Butte</surname>
</string-name>, &#x0201c;<article-title>xCell: Digitally Portraying the Tissue Cellular Heterogeneity Landscape</article-title>,&#x0201d; <source>Genome Biology</source>
<volume>18</volume>, no. <issue>1</issue> (<year>November 2017</year>): <fpage>220</fpage>, <pub-id pub-id-type="doi">10.1186/s13059-017-1349-1</pub-id>.<pub-id pub-id-type="pmid">29141660</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0066"><label>66</label><mixed-citation publication-type="journal" id="hon70104-cit-0066">
<string-name>
<given-names>R. J.</given-names>
<surname>Stubbins</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Cherniawsky</surname>
</string-name>, and <string-name>
<given-names>A.</given-names>
<surname>Karsan</surname>
</string-name>, &#x0201c;<article-title>Cellular and Immunotherapies for Myelodysplastic Syndromes</article-title>,&#x0201d; <source>Seminars in Hematology</source>
<volume>61</volume>, no. <issue>6</issue> (<year>December 2024</year>): <fpage>397</fpage>&#x02013;<lpage>408</lpage>, <pub-id pub-id-type="doi">10.1053/j.seminhematol.2024.09.006</pub-id>.<pub-id pub-id-type="pmid">39426936</pub-id>
</mixed-citation></ref><ref id="hon70104-bib-0067"><label>67</label><mixed-citation publication-type="journal" id="hon70104-cit-0067">
<string-name>
<given-names>A. M.</given-names>
<surname>Brunner</surname>
</string-name>, &#x0201c;<article-title>Novel Immune Directed Therapies in Myelodysplastic Syndromes and Acute Myeloid Leukemia</article-title>,&#x0201d; <source>Current Opinion in Hematology</source>
<volume>30</volume>, no. <issue>2</issue> (<year>March 2023</year>): <fpage>38</fpage>&#x02013;<lpage>44</lpage>, <pub-id pub-id-type="doi">10.1097/moh.0000000000000749</pub-id>.<pub-id pub-id-type="pmid">36728945</pub-id>
</mixed-citation></ref></ref-list></back></article>